Press releases - Ypsomed - United Kingdom

Ypsomed signs master agreement for range of injection systems

28/09/2017 - 16:12 Press Releases Ypsomed Group

Burgdorf – Hanmi Pharmaceutical Co., Ltd. has three biotechnology proteins in its project portfolio that are in various stages of development and approval.

Ypsomed's ServoPen® for the treatment of Parkinson's disease

28/09/2017 - 12:49 Press Releases Ypsomed Group

Burgdorf – Austrian specialist pharmaceutical company, Ever Pharma, now offers the D-mine Pen for the treatment of Parkinson patients with apomorphine. This reusable pen, which is based on the Ypsomed ServoPen platform, facilitates subcutaneous administration with its patient friendly design.

Go-ahead for Ypsomed’s new production facility in Schwerin

27/09/2017 - 07:00 Press Releases Ypsomed Group

Burgdorf – On 26th September 2017, groundbreaking took place for Ypsomed’s new production facility in the Industrial Park of Schwerin, Germany. Ypsomed is to invest over EUR 100 million in the new production site. Production will commence during the first half of 2019. Ypsomed plans to create roughly 150 jobs in the region over the next five years.

Ypsomed to separate from Insulet and extend its portfolio with an own patch pump in the mid-term

21/07/2017 - 07:00 Press Releases Ypsomed Group

Burgdorf – Ypsomed has been the exclusive distributor for the mylife^™ OmniPod^® patch pump outside the USA since 2010. During this period, Ypsomed established therapy with the innovative insulin pump in Europe, gaining market shares of up to 20% in part. The distribution agreement with Insulet Corp. will end as per 30 June 2018. The parties could not agree on extending the contract as the price demanded by Insulet Corp. would have made continued economic viability impossible. Ypsomed is well set for the future and will introduce its own tubeless mylife^™ YpsoPod^® insulin pump in the mid-term.

Ypsomed accelerates growth significantly

24/05/2017 - 07:00 Press Releases Ypsomed Group

Burgdorf – In the financial year 2016/17, the Ypsomed Group generated consolidated sales of CHF 389.6 million (previous year: CHF 336.9 million). Compared with the previous year, this represents an increase in sales of 15.6%. The operating results (EBIT) also increased by 24.4% compared to the previous year, from CHF 44.4 million to CHF 55.3 million. Profitability at the EBIT level has now risen to 14.2% (previous year: 13.2%). Compared with the previous year, the net profits were raised by 29.1% from CHF 35.8 million to CHF 46.2 million. Some demanding tasks lie ahead for the coming financial year, but Ypsomed remains confident and again expects a growth in sales of approximately 15% for the financial year 2017/18.